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Pituitary tumours are predominantly monoclonal in origin and
account for approximately 10% of all intracranial neoplasms
(Alexander et al, 1990; Herman et al, 1990). Although a multi-step
aetiology involving both oncogenes and tumour suppressor genes
(TSGs) has been proposed for the development of endocrine
tumours (Melmed, 1994; Thakker, 1993), analogous to other
tumour types, many of the changes are less well-defined owing, in
part, to the rarity of the invasive and malignant phenotype. Thus,
with the exception of the gsp oncogene, a constitutively active
form of the Gs protein occurring in up to 40% of somatotrophi-
nomas (Landis et al, 1989; Clementi, 1990; Lyons et al, 1990;
Boggild et al, 1994), only a few reports have detailed isolated
instances of activating mutations in known oncogenes (reviewed
by Pei and Melmed, 1996; Shimon and Melmed, 1997). Studies of
known TSGs have described the loss of CDKN2/p16 expression,
principally through CpG island methylation, in the majority of
pituitary tumour subtypes studied (Woloschak et al, 1996, 1997;
Farrell et al, 1997a; Simpson et al, 1999). However, loss of func-
tion of other common TSGs, as evidenced by deletion or mutation
of the retinoblastoma (Rb) (Cryns et al, 1993; Zhu et al, 1994) or
p53 gene (Sumi et al, 1993) are infrequent events.
Deletion mapping at the site of presumed or putative TSGs has
defined losses associated with particular chromosomal loci in
pituitary tumours. Whilst some of these losses (chromosome 9p)
appear to occur early in pituitary tumorigenesis (Farrell, 1997b)
others are associated with the invasive and malignant phenotype
including losses on chromosomes 11q13, 13q12–14, 10q26 and
1p (Bystrom et al, 1990; Boggild et al, 1994; Pei et al, 1995; Bates
et al, 1997). The multiple endocrine neoplasia type 1 (MEN1) gene
on 11q13 has now been independently cloned by two groups
(Chandrasekharappa, 1997; European Consortium on MEN1,
1997a) and frequent germline mutations, which collectively
encompass all coding exons, in familial (Agarwal et al, 1997;
Chandrasekharappa et al, 1997; European Consortium on MEN1,
1997a; Basset et al, 1998) and sporadic forms of the disease
(Agarwal et al, 1997) have been described. In addition to familial
tumours, recent studies have described presumed inactivating
somatic mutations in several different sporadic tumour types,
including parathyroid tumours (Heppner et al, 1997), gastrinomas
and insulinomas (Zhuang et al, 1997a) and in two of four pituitary
tumours (Zhuang et al, 1997b) with evidence of loss of heterozy-
gosity (LOH) within the critically deleted region on 11q13. Since
we and others (Bystrom et al, 1990; Thakker et al, 1993; Boggild
et al, 1994; Bates et al, 1997) have shown that a significant propor-
tion of sporadic pituitary tumours harbour deletions (8–40%;
reviewed by Thakker, 1996) that map to the critically deleted
region of the MEN1 gene, we tested the hypothesis that inacti-
vating mutations would be found on the retained allele in these
tumours. We therefore carried out complete sequence analysis of
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loss of heterozygosity (LOH) telomeric to the menin gene. However, the overall pattern of loss in informative cases was indicative of non-
contiguous deletion that brackets the menin gene. Sequence analysis of all MEN1 coding exons and flanking intronic sequence, in tumours
and matched patient leucocyte DNA, did not reveal mutation(s) in any of the 23 tumours studied. A benign polymorphism in exon 9 was
encountered at the expected frequency, and in seven patients heterozygous for the polymorphism the tumour showed retention of both copies
of the menin gene. Reverse transcription polymerase chain reaction analysis of ten evaluable tumours and four normal pituitaries revealed the
presence of the menin transcript. Whilst these findings suggest that gene silencing is unlikely to be mechanistic in sporadic pituitary
tumorigenesis, they do not exclude changes in the level or stability of the transcript or translation to mature protein. Our study would support
and extend very recent reports of a limited role for mutations in the MEN1 gene in sporadic pituitary tumours. Alternatively, these findings may
point to an, as yet, unidentified tumour suppressor gene in this region.
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all coding exons of the MEN1 gene in 23 sporadic pituitary
tumours, of various subtypes, showing LOH on 11q13. In those
cases where sufficient tumour material was available, we used
reverse transcription polymerase chain reaction (RT-PCR) to
detect expression of the menin transcript.
MATERIALS AND METHODS
Sufficient DNA was available from 23 pituitary tumours (15
somatotrophinomas, two prolactinomas, one corticotrophinoma
and five non-functioning) and matched patient blood DNA
previously shown to have sustained allelic deletion at markers
tightly linked to the MEN1 locus (Thakker et al, 1993; Boggild
et al, 1994; Bates et al, 1997). Tumour samples were collected
retrospectively, following standard histological assessment.
Tumours were defined as invasive or non-invasive, as pre-
viously described (Bates et al, 1997), on the basis of computerized
tomography and/or magnetic resonance imaging, and graded using
criteria based on a modified Hardy classification. In addition, we
studied 15 histologically normal post-mortem pituitaries obtained
within 12 h of death. Normal pituitaries were fixed, then
embedded in paraffin and confirmed normal by routine
microscopy prior to DNA extraction. Tumour number, subtype
and radiological grade are shown in Table 1. Prior to the studies
detailed below, all tumours and matched patient blood DNA were
reassessed with the microsatellite marker PYGM to confirm our
previous findings (Boggild et al, 1994; Thakker et al, 1993; Bates
et al, 1997) of LOH at this marker. Confirmation of LOH at
this marker formed the basis of the initial selection criteria for
inclusion in the study.
Tumour DNA and RNA preparation
Ten 5-mm sections were taken from the paraffin-embedded
tumour. A single section was subjected to haematoxylin and eosin
staining allowing tumour identification and subsequent micro-
dissection from the remaining slides. This procedure provides a
microscopically homogeneous sample with minimal contamina-
tion from non-neoplastic cells. DNA was extracted by prolonged
(3–5 days) Proteinase K (0.2 mg ml–1) digestion in 50 mM
Tris-HCl (pH 8.5), 1 mM EDTA and 0.5% Tween-20. Samples
were heated to 99°C for 10 min and subjected to brief centrifuga-
tion. Supernatants were removed to fresh tubes and stored at
4°C. In addition, constitutive DNA was extracted from matched
blood samples using commercially available reagents (Nucleon 1;
Scotlab, Strathclyde, UK).
Where sufficient suitable (< 20% contamination by normal cells)
solid tumour was available, RNA was extracted using a single-step
method of RNA isolation as previously described (Chomczynski
and Sacchi, 1987). A portion of the solid tumour was simultane-
ously subject to DNA extraction (see above) and the pattern of
microsatellite losses, evident in the microdissected tumours,
confirmed prior to RT-PCR studies. RNA integrity was verified on
0.8% denaturing agarose gels after ethidium bromide staining.
LOH analysis
The previously described microsatellite marker PYGM and other
markers within the 11q13 critically deleted region (Manickam
et al, 1997), inferred from LOH studies, were used to determine
the pattern and extent of allelic deletion. The microsatellite
markers and their relative position are shown in Figure 3. The
markers PYGM and D11S4936 define the centromeric and telo-
meric extent of a 300 kb interval (respectively) that encompasses
the MEN1 gene. D11S4946 is a MEN1 intragenic marker and
D11S4940 lies within this interval (Figure 3). Primer sequences
were obtained from the Genome DataBase. PCRs were carried out
in 25-ml volumes with 1.5 mM magnesium chloride, 200 mM each
of dATP, dGTP, dTTP and dCTP, 2 pmol of each primer, template
DNA (as serial dilutions) and 1 unit of Taq DNA polymerase. PCR
was carried out for 25–30 cycles. Constitutive and tumour DNA
products were run adjacently and separated on 8% non-denaturing
polyacrylamide gels, fixed in 10% methylated spirit/0.5% acetic
acid for 6 min and then incubated in 0.1% aqueous silver nitrate
for 15 min. Following two brief washes in distilled water, products
were visualized by development in 1.5% sodium hydroxide/0.1%
formaldehyde.
In addition, for the microsatellite markers in which one of the
primers is located within an Alu repeat (D11S4946, D11S4940 and
D11S4936) (Manickam et al, 1997), LOH analysis was also
assessed by g32P-ATP end-labelling of the non-Alu primer. Where
assessable, both techniques of visualization were concordant for
assignment of LOH status. However, considerably fewer of the
cohort gave resolvable bands that were assessable by the end-
labelling techniques than by silver staining, we therefore used the
latter technique for all of the markers employed in this study.
Allelic loss was identified by a reduction in band intensity of
greater than 80% or the absence of one of the expected PCR 
products in the amplified DNA. Template DNA was serially diluted
prior to PCR amplification, allowing a direct comparison of dilu-
tions that produced similar product intensities between constitutive
DNA and the retained allele(s) in the matched tumour sample.
MEN1 sequence analysis
The MEN1 gene comprises ten exons (exon 1 is not translated).
Sequencing reactions of all coding exons encompassed
Table 1 Patient numbers, pituitary tumour subtype and radiological grade.
All tumours have previously been reported as showing loss of the
microsatellite marker PYGM
Patient no. Tumour subtype Grade Mutationa
1 Corticotrophinoma 4 –
3 Somatotrophinoma 3 –
20 Somatotrophinoma 2 –
48 Somatotrophinoma 2 –
51 Prolactinoma 2 –
55 Somatotrophinoma 3 –
99 Somatotrophinoma 2 –
101 Somatotrophinoma 3 –
103 Somatotrophinoma 3 –
132 Non-functional 2 –
133 Somatotrophinoma 3 –
167 Somatotrophinoma 2 –
171 Somatotrophinoma 3 –
173 Somatotrophinoma 2 –
196 Somatotrophinoma 1 –
197 Non-functional 3 –
214 Somatotrophinoma 2 –
228 Prolactinoma 3 –
230 Non-functional 3 –
231 Somatotrophinoma 3 –
258 Non-functional 3 –
259 Non-functional 4 –
363 Somatotrophinoma 3 –
a(–) absence of mutation.46 WE Farrell et al
British Journal of Cancer (1999) 80(1/2), 44–50 © Cancer Research Campaign 1999
exon–intron boundaries using, in total, 15 primer pairs as
described by the European Consortium on MEN1 (1997a). PCR
products were directly sequenced using a standard dideoxy
protocol (USB; Sequenase Version 2.0 DNA Sequencing Kit)
and normal and tumour DNA sequences were compared. All 23
tumours were subjected to sequence analysis of the nine coding
exons using both sense and antisense oligonucleotide primers.
RT-PCR analysis
Sufficient RNA was available from ten of the tumours shown to
harbour allelic deletion within the 11q13 MEN1 interval. A total of
2–5 mg of RNA was heated to 65°C for 10 min in the presence of
0.2 mg random hexamer primer and then snap-cooled on ice in a
total volume of 12 ml. In a final volume of 20 ml, the reaction
mixture contained 200 mM of dATP, dGTP, dTTP and dCTP, 1X
first strand buffer mix, 10 mM dithiothreitol and 2 units of reverse
transcriptase (Superscript II Rnase H-Reverse Transcriptase;
GibcoBRL, Life Technologies Ltd, UK). The reaction mixtures
were then incubated at 25°C for 10 min and 42°C for 1 h as
described by the manufacturers. The reaction was stopped by
heating to 95°C for 5 min and cDNAs stored at –20°C. PCR
amplification of the resulting cDNA was achieved with primers
designed to encompass intron 8 of the MEN1 gene to distinguish
possible contamination by genomic DNA. The primer sequences
used comprised an exon 8 upstream primer, CCAATGATGT-
CATCCCCAA, and exon 9 downstream primer, CCTG-
GAGGGCGGAACCT. PCR amplification was limited to 30
cycles to ensure amplification in the exponential phase. In addi-
tion, identical conditions were used for both normal and
tumourous pituitaries, thus allowing semi-quantitative comparison
relative to an HPRT internal control (see below). Visualization of
the resulting 115 bp product was carried out as described above.
To confirm cDNA integrity, in the tumour samples, a portion of the
housekeeping gene HPRT was co-amplified from tumour cDNA,
forward primer TGACCAGTCAACAGGGGACA, reverse primer
GCCTGACCAAGGAAAGCAAAGTC (product size 135 bp). In
all cases appropriate controls, including omission of reverse
transcriptase, failed to produce an amplified product.
RESULTS
We first analysed 23 pituitary tumours and matched leucocyte
DNA for LOH on chromosome 11q13 within the minimal interval
of the MEN1 gene inferred by LOH studies (Manickam et al,
1997). Tumour subtype and grade are shown in Table 1 and have
been previously investigated by us in several recent reports
(Boggild et al, 1994; Thakker et al, 1993; Bates et al, 1997; Farrell
et al, 1997b). Tumours were initially selected on the basis of LOH
at the polymorphic marker PYGM, located centromeric and within
50 kb of the MEN1 gene (European Consortium on MEN1,
1997b). Using recently described microsatellite markers in the
MEN1 interval (Manickam et al, 1997; Figure 3) we determined
which of these 23 tumours had sustained loss at the intragenic
locus, D11S4946, and the telomeric loci, D11S4940 and D11S436.
Tumours were initially re-evaluated with the marker PYGM to
confirm our previous reports of LOH at this marker (Thakker et al,
1993; Boggild et al, 1994; Bates et al, 1997). Further LOH
studies of these tumours were undertaken. D11S4936 located at
the telomeric boundary of the interval showed LOH in three of
13 informative cases, and D11S4940, in five of 14 informative
cases (Figure 1 and summarized in Figure 3). Overall, the data
show that, of the 23 tumours with evidence of LOH at PYGM,
five tumours had sustained deletion at one or more markers that lie
telomeric to PYGM. However, in two of these tumours (51 and
214) that were informative for the intragenic marker D11S4946
and showed retention of heterozygosity, the overall pattern of loss
demonstrates non-contiguous deletion that brackets, but excludes,
the MEN1 gene. The other two tumours, informative for D11S4946
(55 and 231), also showed retention of both copies of the menin
gene, and in these cases loss were confined to the marker PYGM.
Since the more distal markers to PYGM were either frequently
uninformative or did not yield an evaluable product, we attempted
to use the other recently described markers in this region
(Manickam et al, 1997). Despite repeated attempts under different
conditions, we were unable to resolve assessable PCR products
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Figure 1 Representative examples of LOH in sporadic pituitary tumours. All
tumours in the study show loss of one copy of the marker PYGM. In addition,
the Figure shows examples of LOH at other markers in the critically deleted
region inferred from LOH studies. In all cases, DNA from microdissected
tumours are compared to matched patient leucocyte DNA and run adjacently.
Tumour numbers are shown above the lanes and the microsatellite markers
on the left of each matched tumour normal DNA pair. Arrows show LOH as a
substantial decrease in the intensity of one of the alleles in the tumour DNA
relative to the matched leucocyte DNA. The absence of an arrow indicates
retention of heterozygosity in the tumour
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Figure 2 Representative examples of RT-PCR analysis of a portion of the
menin transcript in tumours showing LOH on 11q13 and from normal
pituitaries. The position of the amplified menin product (115 bp) and the
co-amplified HPRT transcript (135 bp) are shown on the left of the figure
and are arrowedMEN1 gene in pituitary tumours 47
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from either tumour or leucocyte DNA (data not shown). No losses,
at any of the microsatellite markers used in this study, were found
in any of 15 normal pituitaries evaluated (data not shown).
The presence of somatic mutations in the gene encoding menin
was investigated by direct sequence analysis of all coding exons
together with their flanking intronic sequences. No mutations were
detected in any of the 23 tumours studied and, in all cases, tumours
were analysed and compared to matched patient leucocyte DNA.
A published polymorphism in exon 9 (D418, GAC/GAT, 54% C:
42% T; Agarwal et al, 1997; Chandrasekharappa et al, 1997;
Bassett et al, 1998) was encountered at the expected frequency and
was identical in DNA from tumours and matched leucocytes. In
five of the 23 cases, both tumour and matched leucocyte DNA (99,
101, 133, 196, 197, 214, 230) were heterozygous for the poly-
morphism. Thus, collectively, the presence of either the exon 9
polymorphism and/or retention of heterozygosity for the MEN1
intragenic marker D11S4946 demonstrated retention of both
alleles of the menin gene in ten of 23 tumours studied.
Since we were unable to detect mutation(s) in the coding region
of the menin gene, alternative mechanisms of gene silencing found
in other tumour types, including mutation in the promoter region
or hypermethylation of a CpG island, were indirectly investigated.
For ten of the tumours in this study, sufficient solid tumour was
available for RT-PCR analysis. Microscopically, the tumours
comprise > 80% tumour cells and, prior to RT-PCR analysis, we
re-assessed their LOH status. All solid tumour showed the same
pattern of LOH as their microdissected counterparts, thus demon-
strating minimal contamination from surrounding or infiltrating
‘normal’ cells. In all ten cases, and in four histologically normal
pituitaries, we detected the presence of a portion of the menin tran-
script (Figure 2 and summarized in Figure 3). Whilst we did not
attempt to quantify transcript expression levels, a similar signal
intensity was apparent in both tumourous and normal pituitaries
when the co-amplified signal for HPRT is taken into account.
These results would suggest that the menin transcript in the
tumour samples was not simply a consequence of a ‘leaky gene’.
DISCUSSION
Previous studies by our own and other groups have described
11q13 LOH in sporadic (Bystrom et al, 1990; Boggild et al, 1994;
Thakker et al, 1993; Bates et al, 1997; Zhuang et al, 1997b) and
MEN1-associated pituitary adenomas (Dong et al, 1997). In addi-
tion to pituitary tumours other sporadic endocrine tumours not
associated with MEN1 show variable, often frequent, LOH
(3–78%) on 11q13 (Friedman et al, 1992; Lida et al, 1995;
Jakobovitz et al, 1996; Debelenko et al, 1997). The recent cloning
of the MEN1 gene and identification of germline mutations, in
both familial and sporadic forms of this disease (Agarwal et al,
1997; Chandrasekharappa et al, 1997; European Consortium on
MEN1, 1997a; Bassett et al, 1998), has facilitated the identifica-
tion of mutations in tumours not associated with the MEN1
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Figure 3 Summary chart of 11q13 allelic status in 23 pituitary tumours. The left of the Figure is a schematic representation of a portion of chromosome
11q where the crossbars represent the approximate map positions of the microsatellite markers. The markers used in this study, PYGM to D11S4936, define the
centromeric and telomeric (respectively) boundary of the critically deleted region inferred from LOH studies. In addition, the Figure shows the status of the exon
9 polymorphism in all tumours included in the study (*) and the RT-PCR summary for ten tumours investigated. Patient numbers are shown at the top of the
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syndrome. To this end, somatic mutations have recently been identi-
fied in sporadic tumours of the parathyroid (54%) (Heppner et al,
1997), gastrinomas and insulinomas (33% and 17% respectively)
(Zhuang et al, 1997b) with evidence, in the majority of cases, of LOH
within the critically deleted region on 11q13. Two studies of sporadic
pituitary tumours have been reported to date (Zhuang et al, 1997b;
Prezant et al, 1998). In the first report, MEN1 mutations were found
in two of 37 sporadic pituitary tumours investigated (Zhuang et al,
1997b); however, the second study failed to detect mutation in any of
45 tumours investigated (Prezant et al, 1998).
In this study we further investigated both clinically active and
inactive pituitary tumours with evidence of LOH at the microsatel-
lite marker PYGM. The combined data showed that, of 23 tumours
with evidence of LOH at PYGM, five had sustained concomitant
loss at one or more distal (telomeric) markers within the 300 kb
interval. However, in those cases informative for the intragenic
marker D11S4946 and/or the exon 9, polymorphism retention of
heterozygosity defines either a region of non-contiguous deletion
or the deletions telomeric extent. Non-contiguous deletions are not
without precedent in sporadic pituitary tumours since in a previous
report of LOH on chromosome 9p we identified non-contiguous
deletions that bracket, but specifically exclude, the TSGs p15 and
p16 (Farrell et al, 1997b).
Complete sequence analysis of all coding exons, of the gene
responsible for MEN1, with evidence of LOH within this region,
did not reveal mutation(s) in any of the 23 tumours studied. In other
studies of sporadic tumours reported to date (Heppner et al, 1997;
Zhuang et al, 1997a, 1997b; Bassett et al, 1998; Prezant
et al, 1998) sequence abnormalities were initially detected either by
dideoxy fingerprinting (Heppner et al, 1997; Prezant et al, 1998) or
SSCP analysis (Zhuang et al, 1997a, 1997b; Basset et al, 1998)
respectively. Although both of these techniques facilitate rapid
screening both may fail to detect mutations. Our direct sequencing
strategy circumvented the inherent problems associated with these
two techniques and it is therefore unlikely that we had failed to
identify mutations present within the coding exons or their flanking
intronic sequences. The reliability of our sequencing data was
further supported by the detection of a benign polymorphism in
exon 9 of the MEN1 gene, showing complete concordance between
tumours and matched leucocyte DNA. In seven cases that were
heterozygous for this polymorphism, this showed retention of both
copies of the menin gene. The combined data of tumours heterozy-
gous for the polymorphism and/or retention of the intragenic marker
(D11S4946) show that, in ten of the tumours studied, both copies of
the menin gene are retained. Thus, whilst all tumours were initially
selected on the basis of LOH at the microsatellite marker PYGM
that lies within 50 kb of the MEN1 locus, in these cases it was not
accompanied by loss of either copy of the menin gene. The cloning
and identification of the gene responsible for MEN1 has been espe-
cially challenging, due in part to this region being particularly gene-
rich. Our results may point to the involvement of another TSG in
this region in pituitary tumours and perhaps in other sporadic
endocrine tumour types with evidence of LOH on 11q13. The
recently described microsatellite markers in the MEN1 region and
other markers on this chromosomal arm (European Consortium on
MEN1, 1997b; Manickam et al, 1997) will substantially aid the
identification of potentially novel genes and their protein products
with tumour suppressor activity in sporadic tumours.
The first report describing mutations of the MEN1 gene in
sporadic pituitary tumours (Zhuang et al, 1997b) initially screened
38 tumours for allelic deletion using either interphase fluorescence
in situ hybridization (FISH) or microsatellite analysis.
Collectively, the two techniques identified deletions in four
tumours (two by FISH and two by LOH analysis). However, only
the tumours showing LOH by microsatellite analysis were found
to harbour mutations. The discordance between this first report
and the present study is difficult to explain since we specifically
targeted only those tumours with evidence of LOH (as defined by
microsatellite analysis) within the critically deleted region of the
MEN1 interval, for sequence analysis. The difference may be
partly explained by the number of tumours within each particular
subtype. The majority of tumours in our study comprised somato-
trophinomas, since these show the highest frequency of LOH on
11q13. However, in the study by Zhuang et al (1997b), signifi-
cantly more corticotrophinomas were studied, of which, the one
shown to harbour allelic deletion had also sustained a mutation in
the retained allele. Our study would discount a role for mutation in
the menin gene in pituitary tumours with evidence of LOH on
11q13 and in somatotrophinomas in particular. Indeed, the only
other report of sporadic pituitary tumours (Prezant et al, 1998) also
failed to detect mutation in the menin gene in 45 tumours investi-
gated. In the other two studies of sporadic tumours reported to
date, deletions were assigned either by microsatellite analysis
(parathyroid tumours; Heppner et al, 1997) or interphase FISH
(gastrinomas and insulinomas; Zhuang et al, 1997a). Whilst both
techniques identified tumours that were then found to have
sustained a mutation in the remaining allele, they also identified a
significant number of tumours with allelic loss that was not
accompanied by mutation in the remaining allele.
In the study reported by Zhuang et al (1997b), two sporadic
pituitary tumours had loss of one copy of the MEN1 gene without
gene mutation in the remaining copy. In both cases, loss was
assigned using interphase FISH whilst in the two tumours shown
to have sustained mutation allelic deletion was determined by
microsatellite analysis. Among the possible reasons these authors
propose for the absence of mutations in these tumours is that they
may contain mutations in promoter regions of the MEN1 gene
that was not screened or that alternative mechanisms, such as
hypermethylation of a CpG island, may inhibit transcription of
the MEN1 gene in these tumours. To determine the role of
alternate mechanisms of gene silencing we used RT-PCR analysis.
In both normal and tumourous pituitaries the presence of the
menin transcript was readily detectable and similar results are
reported by Prezant et al (1998). The role of methylation as a
mechanism of gene silencing in pituitary tumours has very
recently been established (Farrell et al, 1997a; Woloschak et al,
1997; Simpson et al, 1999). These two studies have shown
frequent inactivation of the p16 gene by CpG island methylation,
whilst in an earlier study we showed frequent non-contiguous
deletion on chromosome 9p in pituitary tumours that bracketed,
but excluded, the p16 gene (Farrell et al, 1997b). Whilst our study
did not reliably allow us to draw any conclusions regarding the
relative levels of transcription between normal and tumourous
tissue, they support the view that mutation in non-coding MEN1
sequences or epigenetic mechanisms, such as hypermethylation
are unlikely to play a role in transcriptional silencing. However,
the availability of antibodies to the menin protein may well define
reduced expression of this protein or loss through aberrations in
post-transcriptional processing of the menin transcript as mecha-
nistic in pituitary tumorigenesis.MEN1 gene in pituitary tumours 49
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In summary, our study shows an absence of mutation in the
coding region of the MEN1 gene in sporadic pituitary tumours of
various subtypes despite loss of microsatellite markers within the
critically deleted region encompassing this gene. The menin tran-
script was readily detectable in the tumours examined suggesting
that gene silencing is unlikely to be mechanistic in pituitary
tumorigenesis.
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